C

China Meheco Group Co Ltd
SSE:600056

Watchlist Manager
China Meheco Group Co Ltd
SSE:600056
Watchlist
Price: 10.43 CNY -0.57% Market Closed
Market Cap: ¥15.6B

China Meheco Group Co Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Meheco Group Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
C
China Meheco Group Co Ltd
SSE:600056
Operating Income
¥923.2m
CAGR 3-Years
-4%
CAGR 5-Years
-16%
CAGR 10-Years
-1%
COSCO SHIPPING Development Co Ltd
SSE:601866
Operating Income
¥3.8B
CAGR 3-Years
-11%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Sichuan New Energy Power Co Ltd
SZSE:000155
Operating Income
¥1B
CAGR 3-Years
-16%
CAGR 5-Years
15%
CAGR 10-Years
N/A
C
CITIC Metal Co Ltd
SSE:601061
Operating Income
¥1.5B
CAGR 3-Years
18%
CAGR 5-Years
1%
CAGR 10-Years
N/A
C
China National Uranium Co Ltd
SZSE:001280
Operating Income
¥2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
JINGDONG Industrials Inc
HKEX:7618
Operating Income
¥2.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China Meheco Group Co Ltd
Glance View

China Meheco Group Co., Ltd., established in 1984, stands as a prominent player in the Chinese pharmaceutical and healthcare sector. As the company evolved over the decades, it navigated the complex Chinese market by strategically positioning itself across the entire pharmaceutical value chain. This involved investing heavily in research and development, securing partnerships with both domestic and international pharmaceutical companies, and streamlining its distribution network to enhance efficiency. Such endeavors have enabled China Meheco to develop and distribute a wide range of medical products, including active pharmaceutical ingredients, finished drugs, medical devices, and traditional Chinese medicines. The company leverages its robust R&D capabilities to continually bring innovative products to market, which has been a significant source of its revenue. China Meheco's business model thrives on its expansive distribution network and strategic collaborations. By aligning with global pharmaceutical giants, the company not only gains access to cutting-edge technologies and advanced formulations but also expands its market reach beyond China. This dual strategy of innovation and partnership ensures a steady flow of products that cater to diverse healthcare needs. Furthermore, China Meheco capitalizes on its local expertise and deep understanding of regulatory frameworks, allowing it to maneuver efficiently within China's complex healthcare landscape. This approach underpins its ability to capture substantial market share in a competitive industry, driving profitability and positioning the company as a key player in the global pharmaceutical arena.

Intrinsic Value
15.12 CNY
Undervaluation 31%
Intrinsic Value
Price ¥10.43
C

See Also

What is China Meheco Group Co Ltd's Operating Income?
Operating Income
923.2m CNY

Based on the financial report for Sep 30, 2025, China Meheco Group Co Ltd's Operating Income amounts to 923.2m CNY.

What is China Meheco Group Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-1%

Over the last year, the Operating Income growth was -23%. The average annual Operating Income growth rates for China Meheco Group Co Ltd have been -4% over the past three years , -16% over the past five years , and -1% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett